The Global Non-Small Cell Lung Cancer (NSCLC) treatment market value Expected to reach $7.9 billion by 2020, Finds New Report

The global Non-Small Cell Lung Cancer (NSCLC) treatment market value will increase from $5.1 billion in 2013 to slightly over $7.9 billion by 2020, expanding at a Compound Annual Growth Rate (CAGR) of 6.6%. The report states that this growth will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

Senior Analyst says: “There will be numerous new drug market entries by 2020, and while some will only have a low impact in crowded sectors, other new approvals will benefit patient subpopulations that are untreated by targeted therapies. “Most notably, the squamous cell patient population, which currently relies on generic chemotherapy regimens only, will have access to immunotherapies such as Yervoy (ipilimumab), necitumumab and nivolumab.”

Libberton adds that while some of these drugs' safety profiles are a concern, they have clinically demonstrated improvements or non-inferiority to the efficacy of current segment leaders. Therefore, while Publisher forecasts that these drugs are unlikely to dominate the market and replace chemotherapy, they will offer suitable alternatives and help to diversify treatment options.

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market report provides an assessment of the current Non-Small Cell Lung Cancer (NSCLC) treatment market and evaluates key drivers and barriers to predict global trends to 2020. The report also provides insight into the NSCLC pipeline, including drug distribution by Phase, molecule type and mechanism of action, in addition to an analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements.

Scope

• The report assesses the current NSCLC market and predicts market trends to 2020, analyzing key drivers and barriers
• Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment
• The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs
• An in-depth forecasting model for the NSCLC market, which considers the current marketed therapies in addition to the potential entry of new products to the market. The model comprises a projected outcome with high and low variance results depending on the potential performance of pipeline therapies

Reasons to Buy

• The report will enable clients to develop a strong understanding of NSCLC as a disease and as a market. The current therapeutic needs and future market trends will highlight opportunities and the scope of competition between NSCLC therapeutics
• Understand the NSCLC pipeline and the clinical needs that it is addressing, particularly the ways in which histology affects treatment options and where in the treatment algorithm new products will be positioned, as well as where unmet needs remain
• Develop their knowledge of key products that may enter the market before 2020. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the NSCLC treatment plan and the competition they face

Know more about this report at – http://mrr.cm/ZDQ

Find all Pharmacy Reports at: http://www.marketresearchreports.com/pharmacy